Type 1 diabetes: Continuous glucose monitoring

A closed-loop insulin delivery system may offer significantly better glycemic control than an open-loop system with predictive low glucose suspend in islet transplant candidates with highly unstable type 1 diabetes, research shows.

Sharing continuous glucose monitoring data with a chief follower has multiple quality of life and health benefits for people with type 1 diabetes, a study shows.

People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.

Continuous glucose monitoring is well accepted and reduces time in hypoglycemia among older individuals with type 1 diabetes, report researchers in JAMA.

Impaired awareness of hypoglycemia is associated with an increased risk for severe hypoglycemia and increased fear of hypoglycemia in pregnant women with type 1 diabetes, shows a post-hoc analysis of CONCEPTT data.

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Glycated hemoglobin levels correlate strongly with continuous glucose monitoring-measured average blood glucose and hyperglycemia, but poorly with hypoglycemia, say researchers.

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

Get more on: Hypoglycemia | Devices and technology | Pediatric diabetes

In this paper, the authors report on the current scientific evidence on the effectiveness of continuous glucose monitoring sensor technology in the prevention of severe hypoglycemia and hypoglycemia unawareness [read more].
Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

Get more on:  Devices and technology | Diabetic complications | Type 1 diabetes

Advisory Board member Katharine Barnard scrutinizes the opinion that clinicians should rely on glycemic outcomes when weighing the decision to prescribe a diabetes device [read more].

Get more on: Devices and technology | Glycemic control in type 1 diabetes | Glycemic control in type 2 diabetes